Bone marrow transplantation-related thrombotic microangiopathy (BMT-TMA) is a severe complication partly suspected on the evidence of a microangiopathic haemolysis. Microscopic schistocyte observation confirms the mechanical origin of the haemolysis, but remains a tedious procedure that lacks standardization. Direct measurement of abnormal red blood cell (RBC) fragments is now available on some automated haematology systems. We compared in 131 patients (69 BMT with five BMT-TMA, 38 thrombotic thrombocytopenic syndromes, 11 macroangiopathies, 13 dyserythropoiesis) percentages of microscopic schistocytes and automated RBC fragments (Bayer ADVIA 120) to evaluate the clinical relevance of the automated measurements for BMT-TMA detection. The analyser correlated well with the microscope (intraclass correlation coefficient: 0.82) and quantified RBC fragments with a moderate overestimation ( þ 0.4%) as compared to microscopic counts. BMT patients had higher RBC fragments when they had TMA (1.1 vs 0.4% without TMA). Automated counting was useful to flag BMT-related TMA, particularly when RBC fragments were above 1%. As RBC fragments were frequently detected in BMT patients even without TMA, a threshold of less 1% that ruled out TMA was determined with a 98% negative predictive value. The new RBC fragment automated parameter proved its clinical value to assess BMT-TMA, which might be useful for day-to-day monitoring of the post BMT period.
Schistocyte enumeration is a recurrent laboratory request after bone marrow transplantation (BMT). The presence of schistocytes in the peripheral blood (PB) is considered to be abnormal and indicates the possibility of a thrombotic microangiopathy (TMA), which is a severe and poor prognosis change after BMT. 1 Occurrence of BMT-related TMA raises the possibility of a graft-versus-host disease, a side effect of total-body irradiation, high-dose chemotherapy or cyclosporine/tacrolimus treatment. Thus, frequent (twice a week) schistocyte monitoring is mandatory to detect the laboratory picture of TMA during the follow-up of BMT. 2 The identification of schistocytes is usually carried out under the microscope from a stained PB smear. Since the shapes to which they correspond are frequently questionable, a consensus has been proposed by the Groupe Franc¸ais d'He´matologie Cellulaire (GFHC, French Group of Cellular Hematology). 3 However, schistocyte counting remains a tedious laboratory procedure with a high interobserver variability.
Recently, automated haematology systems (Bayer AD-VIA 120) have offered the possibility of direct measurement of abnormal red blood cells (RBC), in particular RBC fragments, allowing one to obtain accurate cellular counts on an urgent basis without observer-dependent identification. 4 RBC fragments have been found to be in good agreement with the reference microscopic measurement. Interestingly, the negative predictive value of RBC fragments threshold o0.5% was high enough to rule out TMA in a series of patients with thrombocytopenic purpura (TTP) or haemolytic uremic syndrome (HUS). 5 Here, we evaluated the impact of laboratory RBC fragments automated measurement on BMT-related TMA detection. Patients with suspected micro/macroangiopathies or RBC poı¨kilocytosis were also included for comparison.
Materials and methods

Samples
A total of 69 PB specimens originated from patients that had undergone BMT between 2002 and 2003. BMT had been performed for a variety of haematologic malignancies (mainly lymphomas or leukaemias, Table 1 ). Another 62 patients with other haematological disorders were included in the study during the same time. They were suspected of having microangiopathies (TTP, HUS, therapeutic related) or macroangiopathies (patients with heart valve dysfunction or kidney transplants). Patients with PB poı¨kilocytosis were also included in order to check the ability of the automated analyser to flag and quantify RBC fragments.
BMT-related TTP/HUS was diagnosed according to regular features: three of five criteria among evidence of microangiopathic haemolytic anaemia (falling haemoglobin in the presence of schistocytosis without evidence of disseminated intravascular coagulation and with absence of a positive direct antiglobulin test), new thrombocythemia or failure of the platelet count to rise above 20 Â 10 9 /l, lactate deshydrogenase 4450 IU/l, serum creatinine 4150 mmol/l or a 50% rise in baseline, and neurological disturbance such as mental status change or seizures.
The PB specimens were collected in ethylene-diaminetetracetic acid anticoagulated tubes (Vacutainer, Becton Dickinson, San Jose´, CA, USA). All results, positive or negative with regard to schistocytes, were taken into account.
Schistocyte counting
Schistocytes were evaluated by two methods:
Schistocyte optical counting was carried out on PB smears stained using the May-Gru¨nwald Giemsa technique and according to the recommendations proposed by the GFHC: observations by two observers (JFL, SS) of 1000 erythrocytes within their proper spreading zone (no overlap and excluding the feather edge area). Only triangular or 'helmet' shapes were kept as valid.
Direct measurements of RBC fragments in the PB samples were performed on the ADVIA 120 analyser (Bayer Health Care, Tarrytown, NY, USA), from the integrated analysis of the erythrocytes and platelets. The RBC fragments corresponded to events of volume smaller than 30 fl and with a refractive index greater than 1.4, and were provided above a threshold of 10 000 cells/ml. The percentage of schistocytes was subsequently deduced based on the number of erythrocytes measured by the analyser.
Statistics
The degree of agreement among the two observers and the analyser was measured using the intraclass correlation coefficient (ICCC). In order to evaluate the clinical impact of the data, we compared automated RBC fragment detection in the presence or absence of thrombotic events. The sensitivity (Se)/specificity (Sp) of schistocyte/RBC fragment percentages and the negative/positive predictive values (NPV, PPV) were calculated by the usual methods (true/false/positive/negative). For the schistocytes, the reference was the mean of the percentages found by the two observers with a positivity threshold set at 0.2%. For the RBC fragments, the triggering percentage has been calculated previously (0.25% corresponded to an alarm threshold at maximum sensitivity). 
Schistocyte and RBC fragment counting
The mean schistocyte counts are compiled in Table 1 Patients with idiopathic TTP/HUS had higher percentages of RBC fragments or schistocytes as compared to the other groups of patients. In particular, the percentages were higher than for BMT patients, even with BMT-related TMA (Po0.01). Patients with poı¨kilocytosis (thalassemia, iron deficiency, newborn, pyropoı¨kilocytosis, myelofibrosis) had elevated RBC fragments but these only partially corresponded to true schistocytes.
Impact of automated schistocyte counting on clinical practice
We investigated the diagnostic value of the analyser to give relevant information for diagnosis of BMT-related TMA. In order to take into account possible artefacts resulting from blood collection or smearing technique, a threshold of 0.2% was required to confirm the presence of schistocytes in the PB smear (40.2%: positive result; p0.2%: negative result 6 ). For the RBC fragments, the threshold value of maximum sensitivity was previously established at 0.25%. However, more discriminating thresholds that allow gaining PPV without dropping NPV were suggested (1% for ADVIA 120 and 0.5% for microscope). 5 In total, 85% of the patients that had undergone BMT had RBC fragments 40.2% (6% of these patients had RBC fragments 41%) vs 27% of patients with schistocytosis 40.2% (and 4% of patients above 0.5% schistocytes). TMA was confirmed in four of seven patients with RBC fragments more than 1%. All patients with BMT-related TMA had RBC fragments X0.98%, while 3/62 patients without TMA had RBC fragments 1%. Only 9/69 BMT patients had no RBC fragments ( Table 2 ).
The distribution of the patients according to the threshold levels is given in Table 3 . As expected, screening with low thresholds (0.25% for RBC fragment and 0.2% for schistocyte) was more powerful, but with higher thresholds (RBC fragments 1% and schistocytes 0.5%) was more discriminant to assess or eliminate TMA. We calculated then Se, Sp, NPV and PPV for the automated and microscopic analysis according to the thresholds listed (Table 4) . A BMT-related TMA was excluded when RBC fragments fall below the two thresholds retained with NPVs of 100% when RBC fragments o0.5 and 98% when o1%.
Discussion
Occurrence of TMA is one of the most severe complications of BMT. 7, 8 A clinical picture of fever, neurological deficit and renal impairment is associated with thrombocytopenia and microangiopathic haemolysis. 9, 10 Schistocyte detection is mandatory to confirm the TMA. 11 Thus, a schistocyte count is desirable for follow-up of TTP, particularly after BMT, and the identification and counting of schistocytes should be on-demand for emergency request as well as for permanent use in the laboratory. However, the usual visual method (microscopic PB smear examination) lacks standardization of the fragments that can be classified as schistocytes, and is precision-restricted because of the limited number -several hundred -of erythrocytes that are being counted. 6 Automated haematology counters are designed to analyze the physical and chemical properties of thousands of cells. The analysis is observer-independent, has better reproducibility and is the alternative to counting under the microscope. The ADVIA 120 analyser is capable of counting particles of a size close to a platelet and with a refractive index different from a platelet as a result of its haemoglobin content. 4 This area includes schistocytes but also several fragments of uncharacteristic shape: for example, very small microcytes, diverse membrane fragments.
Our aim was to evaluate to what extent the ADVIA 120 analyser is useful in daily practice for the laboratory followup of patients that had undergone BMT. First, the analyser was able to quantify RBC fragments with a moderate overestimation ( þ 0.4%) to schistocytes observed under the microscope, confirming our previous data that pointed out a close relationship in particular for PB specimens having a percentage 41.5%. 5 Second, automated counting was useful to flag BMT-related TMA, particularly when RBC fragments rose above 1%. However, as RBC fragments were frequently detected in BMT samples, thresholds for clinical relevant information had to be set up. Our previous study comparing automated RBC fragments counting with presence or absence of thrombotic disease showed that the 100% NPV was adapted to the thresholds 0.25% of RBC fragments for ADVIA 120 and 0.2% schistocytes for the microscope, but with a poor PPV. Here, we confirmed that more practical thresholds that gained PPV (1% for ADVIA 120 and 0.5% for microscope) could be used. The clinical features correlated particularly well for negative automated RBC fragment counts and, in our hands, ruled out thrombotic disease such as TTP/HUS.
The utility of RBC fragments was doubtful in samples with major RBCs' shape anomalies, whatever their origin. In these cases, fragments of variable shapes or very microcytic RBC were included in the RBC fragment count and masked real schistocytes. Restriction to samples without previously observed poı¨kilocytosis might temper the usefulness of the ADVIA 120 for automated follow-up of BMT in particular indications such thalassemia.
In conclusion, in our hands, the routine determination of the RBC fragments after BMT by the ADVIA 120 was suitable for follow-up in order to exclude BMT-related TMA, and, less specifically, to flag TMA. Nevertheless, the automated results needed to be confirmed by a blood smear examination on the microscope in case of poı¨kilo-cytosis. The new RBC fragment automated parameter might be useful for day-to-day monitoring of post BMT period. 
